ArticleJournal of magnetic resonance imaging : JMRI2026
Characterization of Pulmonary Functional Abnormalities in Systemic Sclerosis Using Xenon MRI.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for "Characterization of Pulmonary Functional Abnormalities in Systemic Sclerosis Using Xenon MRI".Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundXenon MRI is increasingly used to evaluate patients with interstitial lung disease (ILD) and pulmonary hypertension (PH), both of which are common manifestations of systemic sclerosis (SSc). As such, Xe-MRI may be suited to interrogate lung function impairment in SSc. PURPOSE: To characterize xenon MRI signatures in SSc, toward evaluating the utility of xenon MRI as a method to elucidate mechanisms of regional lung function impairment in this population. STUDY TYPE: Prospective. POPULATION: Of 25 participants initially imaged, 21 participants (18 females) with SSc were included. Sixteen healthy volunteers (13 females) were enrolled. FIELDSTRENGTH/SEQUENCE: 3 T, 1-point Dixon imaging using xenon MRI. ASSESSMENT: Xenon MRI measures including ventilation defect percent, membrane uptake, red blood cell (RBC) transfer, RBC defect percent, and RBC oscillation amplitude were generated. Measures were compared across healthy and SSc groups and correlated with standard clinical measures, including demographics, pulmonary function tests, CT lung density measures, and pulmonary artery pressure. STATISTICAL TESTS: Due to a small number of male participants, statistical analysis was limited to female participants. Wilcoxon, t-tests, or Fisher's exact tests were used to compare between healthy and SSc groups. Pearson's correlation was used to correlate xenon MRI with clinical measures. p < 0.05 was considered significant.
resultsDespite a relatively mild burden of pulmonary disease, SSc participants exhibited significantly lower RBC/Membrane ratio (0.25 [IQR, 0.10] vs. 0.34 [0.05]) and RBC transfer (0.22 ± 0.07 vs. 0.28 ± 0.07), and significantly greater RBC defect percent (22.8 [IQR, 16.9] vs. 11.9 [13.7]) compared to healthy volunteers. DATA
conclusionXenon MRI measures, including RBC transfer, RBC/Membrane, and RBC defect percent were markedly different in female SSc patients compared to age-matched healthy volunteers, suggesting that xenon MRI may be an effective method for examining regional impairments to pulmonary gas exchange in SSc. EVIDENCE LEVEL: 2. TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.